Completed PHASE1 INTERVENTIONAL 3-arm NCT01148537

The Effect of Buprenorphine Delivered by Buprenorphine Transdermal System (BTDS) on QT Intervals in Healthy Volunteers

A Randomized, Double-blind, Placebo- & Positive-Controlled, Parallel Group, Dose Escalating Study to Evaluate the Effect of Buprenorphine Delivered by Buprenorphine Transdermal System at 10- and 40-mg Dose Levels on QT Intervals in Healthy Adult Volunteers

Sponsor: Purdue Pharma LP

Conditions Healthy Volunteers

Interventions Avelox (moxifloxacin hydrochloride) tablet Buprenorphine transdermal patch Matching placebo transdermal patch

Updated 7 times since 2017 Last updated: Aug 27, 2012 Started: Jul 31, 2004 Primary completion: Dec 31, 2004 Completion: Dec 31, 2004

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01148537, this PHASE1 trial focuses on Healthy Volunteers and remains completed. Sponsored by Purdue Pharma LP, it has been updated 7 times since 2004, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Dec 2021 — Jul 2024 [monthly]

Completed PHASE1
Jan 2021 — Dec 2021 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE1
Jan 2017 — Feb 2017 [monthly]

Completed PHASE1

First recorded

Jul 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Purdue Pharma LP

Data source: Purdue Pharma LP

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Austin, United States